| Bioactivity | Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with Kis of 221 nM and 230 nM in vital cells and membranes. Amelubant (BIIL 284) is a prodrug of active metabolites BIIL 260 and BIIL 315. Anti-inflammatory activity[1]. | ||||||||||||
| Invitro | Amelubant is a prodrug of active metabolites BIIL 260 and BIIL 315, which are reversible and competitive LTB4 receptor antagonists, with Kis of 1.4, 1.1 nM and 1.7, 1.9 nM in vital cells and membranes, respectively[1]. | ||||||||||||
| Name | Amelubant | ||||||||||||
| CAS | 346735-24-8 | ||||||||||||
| Formula | C33H34N2O5 | ||||||||||||
| Molar Mass | 538.63 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Birke FW, et al. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66. |
Amelubant
CAS: 346735-24-8 F: C33H34N2O5 W: 538.63
Amelubant (BIIL 284) is a potent, oral and long acting LTB4 receptor antagonist, negligibly binds to LTB4 receptor, with
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.